Tradestie Institutional Equity Comparison Engine
ACAD vs CDT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACAD Overall Edge
ACAD Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 15.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
ACAD
ACAD 15.8x vs CDT N/M Fwd P/E
Growth & Margin Winner
ACAD
Op Margin 10.2% vs 0.0% ยท YoY +22.8% vs +0.0%
Momentum & Technical Winner
ACAD
1Y -25.9% vs -86.8% ยท 52W Pos 8% vs 2%
Options & Structure Winner
ACAD
BREAKDOWN (6th %ile IV) vs BREAKDOWN (N/A IV)
ACAD
NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap
$3.0B
1M Return
-15.76%
1Y Return
-25.93%
Forward P/E
15.8x
Unified AI Score
44.8 / 100
HOLD
Tech 38.0
Fund 54.0
Flow 67.0
Mom 60.0
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACAD -25.93%
CDT -86.78%
Spread: +60.85 pp (ACAD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ACAD TTM Op. Margin: 10.2%
CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACAD vs CDT. Trailing 12-month operating profitability (ACAD 10.2% vs CDT 0.0%) and valuation multiples (ACAD 15.8x vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACAD | CDT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $507,528 | Larger Scale | ACAD |
| Trailing P/E Ratio Valuation | 8.3x | N/M | Lower Multiple | ACAD |
| Forward P/E Ratio Valuation | 15.8x | N/M | Lower Multiple | ACAD |
| Revenue Growth (YoY) Growth | +22.8% | +0.0% | Higher Growth | ACAD |
| Operating Margin (TTM) Profitability | 10.2% | 0.0% | Higher Margin | ACAD |
| Net Profit Margin Profitability | 30.1% | 0.0% | Higher Margin | ACAD |
| Return on Equity (ROE) Capital Efficiency | 31.4% | -69.7% | Higher ROE | ACAD |
| 52-Week Range Position Momentum | 8% ($16โ$31) | 2% ($0โ$11) | Stronger Trend | ACAD |
| Beta / 30D Volatility Risk Regime | 0.15ฮฒ ยท 90% Vol | -17.75ฮฒ ยท 10175% Vol | Lower Realized Risk | ACAD |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 31.6 / 100 (SELL) | Higher Composite | ACAD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACAD vs CDT Buy Guide
ACAD
BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACAD nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.